Navigation Links
Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)
Date:5/8/2009

EXTON, Pa., May 8 /PRNewswire/ -- BioTrends Research Group released highlights from its baseline wave of LaunchTrends(TM): SIMPONI, a four wave syndicated research study that will track uptake of the drug from FDA approval through six months post launch. The research is based on results of a survey of 77 Rheumatologists conducted on-line between May 5th and May 7th.

95% of the Rheumatologists surveyed were aware of SIMPONI and about one-third had been called on by SIMPONI sales representatives. Two-thirds reported a favorable reaction to SIMPONI and 83% reported a high interest in learning more about the product. Among those familiar with SIMPONI, nearly all were aware of the monthly dosing intervals, but overall the respondents were less familiar with the product's indications and dose delivery forms. Compared to the other biologics indicated for RA, 43% identified SIMPONI as the "easiest to administer/easiest for patients to take" while 26% gave Abbott's HUMIRA(R) top billing for ease of use. The respondents reported that close to 40% of their severe RA patients could be considered candidates for SIMPONI and that the majority of SIMPONI patients would be switched from other biologic agents. Market share projections suggest that SIMPONI will primarily draw from other TNF-inhibitors and 38% of the respondents suggest that they will prescribe the product for their RA patients as soon as it is available.

Surveyed Rheumatologists are also highly aware of other late stage biologics awaiting approval such as UCB's CIMZIA(R) and Roche's ACTEMRA(R). 62% of the respondents reported a greater interest in ACTEMRA compared to SIMPONI, primarily due to ACTEMRA's novel mechanism of action. Given a choice between SIMPONI and CIMZIA, the respondents reported a greater interest in SIMPONI by a 3:1 margin.

About SIMPONI

Centocor Ortho Biotech, Inc. received FDA approval for SIMPONI(R)'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... (Nasdaq: KNDL ), a,leading, global full-service clinical ... Chief Financial Officer Karl,"Buzz" Brenkert, III will participate ... The conference will be held at the,Loews Miami ... Kendle,s,presentation is scheduled for Tuesday, March 18 at ...
... March 14 Quest Diagnostics,Incorporated (NYSE: DGX ... and services, announced that it is scheduled to ... Conference on,Wednesday, March 19, 2008, at The Loews ... is scheduled to begin at 9:00 a.m.,Eastern Time., ...
... March 14 Wyeth (NYSE: WYE ),announced today ... Annual,Global Healthcare Conference on Wednesday, March 19, 2008 at ... M. Mahady, Senior Vice,President, Wyeth and President, Wyeth Pharmaceuticals., ... at, http://www.wyeth.com and available for replay following the ...
Cached Biology Technology:Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... essential question confronting neuroscientists and computer vision researchers alike is ... Introspectively, we know that the human brain solves this ... something to know what it is. But teaching a ... In research published this fall in the Public Library of ...
... Hay fever (runny nose, sneezing, itchy eyes) is caused by ... These tiny grains bring misery to sufferers through spring and ... weather reports to help sufferers prepare. However new research published ... Allergy shows that, regardless of medication and other allergies, ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:Do you see what I see? 2Do you see what I see? 3Get ready for spring - hay fever worse in spring than summer 2
...
... Cosmid Cloning Kit enables you to prepare, ... unbiased primary cosmid library of genomic DNA ... sublibraries. High efficiency cosmid library construction is ... protocols. First, genomic DNA is randomly sheared ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... Analyzer is a revolutionary multi-capillary electrophoresis system ... platform. It integrates sample loading, electrophoresis, and ... improving the workflow and increasing the productivity ... Benefits of using HDA system are:, ...
Biology Products: